Recursion Pharmaceuticals, Inc. (RXRX) saw its stock price soar 5.08% during intraday trading on Thursday, reflecting a significant positive movement in its share value.
The surge appears to be driven by positive analyst sentiment, specifically from Morgan Stanley, which raised its price target on Recursion Pharmaceuticals to $5.50 from $5.00 while maintaining an Equalweight rating on the stock.